Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

ClinicalTrials.gov ID: NCT05253131

Public ClinicalTrials.gov record NCT05253131. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 4, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor ZEN-3694 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors

Study identification

NCT ID: NCT05253131
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: University of Alabama at Birmingham; Other
Enrollment: 41 participants

Conditions and interventions

Conditions

Interventions

Selumetinib + ZEN-3694 ± Durvalumab Combination Product

Combination Product

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 14, 2026
Primary completion: May 14, 2031
Completion: May 14, 2032
Last update posted: Feb 10, 2026

2026 – 2032

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
The University of Alabama at Birmingham	Birmingham	Alabama	35294	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05253131, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 10, 2026 · Synced May 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05253131 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →